CeNeRx Completes Series C To Fund Trial; Find Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
The biopharma raises a third round of financing to help finish a mid-stage trial for its antidepressant TriRima.
You may also be interested in...
Top Partnering Opportunities In Neuroscience: The Ugly Truth
Consultant notes some promising candidates in a challenging space for investment.
Recapitalization Becomes A Better Alternative In A Weak Economy
Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.